These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
434 related articles for article (PubMed ID: 19621145)
21. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species. Ramírez M; Serrano MC; Castro C; López E; Almeida C; Fernández A; Romero A; Martín-Mazuelos E J Antimicrob Chemother; 2006 Oct; 58(4):861-3. PubMed ID: 16916868 [TBL] [Abstract][Full Text] [Related]
22. [Disk diffusion method for fluconazole susceptibility testing of Candida spp. isolates]. Rodero L; Córdoba S; Vivot W; Campo M; Corfield P; Olguín C; Cuirolo A; Soria M; Guelfand L; Canteros CE; Davel G; Rev Argent Microbiol; 2006; 38(3):155-63. PubMed ID: 17152217 [TBL] [Abstract][Full Text] [Related]
23. EUCAST breakpoints for antifungals. Rodríguez-Tudela JL; Arendrup MC; Cuenca-Estrella M; Donnelly JP; Lass-Flörl C Drug News Perspect; 2010 Mar; 23(2):93-7. PubMed ID: 20369073 [TBL] [Abstract][Full Text] [Related]
24. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Lass-Flörl C; Perkhofer S; Mayr A Mycoses; 2010 Jan; 53(1):1-11. PubMed ID: 20078786 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: comparison with CLSI broth microdilution method. López-Oviedo E; Aller AI; Martín C; Castro C; Ramirez M; Pemán JM; Cantón E; Almeida C; Martín-Mazuelos E Antimicrob Agents Chemother; 2006 Mar; 50(3):1108-11. PubMed ID: 16495281 [TBL] [Abstract][Full Text] [Related]
26. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Arendrup MC; Meletiadis J; Mouton JW; Guinea J; Cuenca-Estrella M; Lagrou K; Howard SJ; Clin Microbiol Infect; 2016 Jun; 22(6):571.e1-4. PubMed ID: 26851656 [TBL] [Abstract][Full Text] [Related]
28. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds. Espinel-Ingroff A; Turnidge J Rev Iberoam Micol; 2016; 33(2):63-75. PubMed ID: 27296911 [TBL] [Abstract][Full Text] [Related]
29. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. Espinel-Ingroff A; Warnock DW; Vazquez JA; Arthington-Skaggs BA Med Mycol; 2000; 38 Suppl 1():293-304. PubMed ID: 11204157 [TBL] [Abstract][Full Text] [Related]
30. Management of antifungal susceptibility testing in Italy: comparative results of 2 nationwide surveys (1999 and 2004) in 102 Italian hospitals. Farina C; Manso E; Sanna S; Lombardi G; Faggi E; Fazii P; Andreoni S Diagn Microbiol Infect Dis; 2007 Feb; 57(2):225-7. PubMed ID: 16935455 [TBL] [Abstract][Full Text] [Related]
31. In vitro susceptibility testing of dermatophytes: comparison of disk diffusion and reference broth dilution methods. Karaca N; Koç AN Diagn Microbiol Infect Dis; 2004 Apr; 48(4):259-64. PubMed ID: 15062918 [TBL] [Abstract][Full Text] [Related]
32. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Arendrup MC; Cuenca-Estrella M; Lass-Flörl C; Hope W; Clin Microbiol Infect; 2012 Jul; 18(7):E246-7. PubMed ID: 22563750 [TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of resistance to antifungals. Rodriguez-Tudela JL; Alcazar-Fuoli L; Cuesta I; Alastruey-Izquierdo A; Monzon A; Mellado E; Cuenca-Estrella M Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S111-3. PubMed ID: 19013333 [TBL] [Abstract][Full Text] [Related]
34. Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. Espinel-Ingroff A; Fothergill A; Ghannoum M; Manavathu E; Ostrosky-Zeichner L; Pfaller MA; Rinaldi MG; Schell W; Walsh TJ J Clin Microbiol; 2007 Jul; 45(7):2180-2. PubMed ID: 17475760 [TBL] [Abstract][Full Text] [Related]
35. Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections. Hamza OJ; van den Bout-van den Beukel CJ; Matee MI; Moshi MJ; Mikx FH; Selemani HO; Mbwambo ZH; Van der Ven AJ; Verweij PE J Ethnopharmacol; 2006 Nov; 108(1):124-32. PubMed ID: 16829001 [TBL] [Abstract][Full Text] [Related]
36. In vitro antifungal and antibacterial activities of pentacycloundecane tetra-amines. Onajole OK; Coovadia Y; Govender T; Kruger HG; Maguire GE; Naidu D; Singh N; Govender P Chem Biol Drug Des; 2011 Apr; 77(4):295-9. PubMed ID: 21241455 [TBL] [Abstract][Full Text] [Related]
37. Susceptibility testing methods of antifungal agents. Ernst EJ Methods Mol Med; 2005; 118():3-12. PubMed ID: 15888930 [TBL] [Abstract][Full Text] [Related]
38. Characterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain. Zalacain A; Obrador C; Martinez JP; Viñas M; Vinuesa T Med Mycol; 2011 Jul; 49(5):495-9. PubMed ID: 21142899 [TBL] [Abstract][Full Text] [Related]
39. Issues in antifungal susceptibility testing. Johnson EM J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i13-8. PubMed ID: 18063599 [TBL] [Abstract][Full Text] [Related]
40. [Methods for studying the in vitro susceptibility of Candida spp. to antifungals]. Abbes S; Trabelsi H; Amouri I; Sallemi H; Nej S; Fatma C; Makni F; Ayadi A Ann Biol Clin (Paris); 2012; 70(6):635-42. PubMed ID: 23207806 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]